Organon & Co. OGN
13.85 USD 0.00 (+0.00%)
At closeNov 10, 2026, 9:07 AM EST
13.83 -0.02 -0.12%
Pre-market · Nov 10, 9:07 AM ET
Day range unavailable
5.69 52-week range 13.88
- YTD
- +93.17%
- 1 year
- +104.28%
News
benzinga.com Reported Saturday, Organon Presents Real-World Data At ACR Showing 1.3% Switchback Rate After Over 16,000 US Veterans Switched From HUMIRA To HADLIMA Analysis of over 16,000 patients switched to HADLIMA® from HUMIRA® (adalimumab) showed a 1.3% switchback rate over a 12-month follow-up period1Data demonstrated the switching cohort had an average…- benzinga.com Organon To Present New Analysis Of Phase 3 Data Evaluating VTAMA Cream In Patients With Atopic Dermatitis, At 2026 ACAAI Annual Scientific Meeting New pooled post-hoc analysis of Phase 3 data evaluates consistency of VTAMA cream efficacy across diverse atopic dermatitis patient subgroupsOrganon (NYSE:OGN), a global healthcare company with a…
benzinga.com Organon To Present Data From Its Current Phase 3 Trial Of MIUDELLA Intrauterine Device At 2026 Society Of Family Planning Annual Meeting Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that Sebela Women’s Health will present interim…- benzinga.com Organon Canada Announces Availability Of NDUVRA To Treat Moderate To Severe Atopic Dermatitis Organon Canada, a global healthcare company, today announces the approval and availability of NDUVRA® (tapinarof cream), 1%, for the topical treatment of moderate to severe atopic dermatitis in adult…
benzinga.com This House of Representative Just Sold Up To $30K In Organon Stock A report on August 12, 2026 shows that Representative Kevin Hern from Oklahoma sale stock in Organon (NYSE:OGN), valued between $2,002 and $30,000. According to the August filing, the transaction…
benzinga.com Organon To Present Results From Post Hoc Analysis Of Pooled Data From Phase 3 Pivotal Trials, ADORING 1 And ADORING 2, Evaluating VTAMA Cream Versus Vehicle At 2026 SPD Annual Meeting The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global…
benzinga.com Organon To Present Phase 3 Data Of VTAMA Cream In Atopic Dermatitis At 2026 Society For Pediatric Dermatology Annual Meeting Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating…
benzinga.com Organon And Samsung Bioepis Expand Their Development And Commercialization Agreement To Provide OGN With Commercialization Rights In Canada To PYZCHIVA, Samsung Bioepis's Biosimilar Referencing STELARA PYZCHIVA® is indicated for the treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis,…
benzinga.com Organon's Supplemental Biologics License Application Gets FDA Approval For TOFIDENCE To Treat Chimeric Antigen Receptor T Cell-Induced Severe Or Life-Threatening Cytokine Release Syndrome Organon (NYSE:OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for…
benzinga.com Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy Major M&A deals this week include: Eli Lilly buys Profluent for $2.2 billion, Lazard buys Campbell Lutyens, FreshRealm bankruptcy.
benzinga.com Organon Q1 Adj. EPS $0.71 Misses $0.83 Estimate, Sales $1.460B Miss $1.484B Estimate Organon (NYSE:OGN) reported quarterly earnings of $0.71 per share which missed the analyst consensus estimate of $0.83 by 14.46 percent. This is a 30.39 percent decrease over earnings of $1.02 per…
benzinga.com Organon Stock's Momentum Score Jumps As $11.75 Billion Sun Pharma Takeover Deal Sparks Global Pharma Consolidation Push Organon momentum score jumps as Sun Pharma's $11.75B all-cash acquisition deal boosts outlook, lifting stock trends across timeframes.- benzinga.com BNP Paribas Downgrades Organon to Neutral, Raises Price Target to $14 BNP Paribas analyst Navann Ty downgrades Organon (NYSE:OGN) from Outperform to Neutral and raises the price target from $12 to $14.
benzinga.com This Old Dominion Freight Line Analyst Is No Longer Bearish; Here Are Top 3 Upgrades For Tuesday Analysts upgraded ODFL, TFII, OGN with positive outlook. See analyst ratings and stock performance.- benzinga.com Piper Sandler Upgrades Organon to Neutral, Raises Price Target to $14 Piper Sandler analyst David Amsellem upgrades Organon (NYSE:OGN) from Underweight to Neutral and raises the price target from $5 to $14.
benzinga.com Nasdaq 100 Eases From Records As Brent Tops $108: Stock Market Today U.S. tech stocks eased from record highs as Brent surges 2.9% to $108 ahead of Big Tech earnings and the FOMC meeting this week.
benzinga.com XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…
benzinga.com Stock Market Today: Dow Futures Fall, S&P 500 Gains As Trump Halts Iran Talks— Organon, SAP, Cheetah Net Supply Chain Service In Focus (UPDATED) Editor’s Note: The future prices of benchmark tracking ETFs, the lede, the economic data and the headline were updated in the story. The S&P 500 and Nasdaq 100 futures pared losses to advance,…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why Is Organon Stock Skyrocketing Monday? Sun Pharma to acquire Organon in an all-cash deal valued at $11.75 billion. OGN shares rise on the acquisition news.
benzinga.com Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the company for $11.75 billion, $2 higher than current price.
benzinga.com Organon To Be Acquired By Sun Pharma In $11.75B Deal, OGN Stock Spikes Nearly 17% On Robinhood 24-Hour Market Organon & Co. has agreed to be acquired by Sun Pharmaceutical Industries in an all-cash deal valued at $11.75 billion, offering shareholders a 103% premium and marking a major step in Sun Pharma's…
benzinga.com Nasdaq 100 Marks Fresh Records, Intel Jumps 23% On AI Chip Mania: Stock Market Today Nasdaq 100 hit a fresh record as Intel surged 23% on a blowout quarter, while Charter Communications cratered and WTI sank 2% on Iran talks.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Sensient Technologies, Chemed, AMD, Arm And Other Big Stocks Moving Higher On Friday U.S. stocks mixed with Dow down 150 pts. Sensient Technologies Corp (NYSE:SXT) shares up 15.8% after beating earnings estimates. Other big gainers include Maxlinear Inc (NASDAQ:MXL), Intel Corp…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Reported Earlier: 'Sun Pharma, Grünenthal Are Said to Vie for US-Listed Organon' - Bloomberg https://www.bloomberg.com/news/articles/2026-04-16/sun-pharma-grunenthal-are-said-to-vie-for-us-listed-organon
- benzinga.com Organon Says VTAMA Creamwas Granted Strong, Evidence-Based Recommendation By AAD In 2026 Guidelines For Management And Treatment Of AD In Pediatric Patients, Published On April 7 The American Academy of Dermatology (AAD) provided a strong, evidence-based recommendation for the use of VTAMA cream, the only steroid-free topical treatment the AAD found to be supported by a high…
benzinga.com Dow Dips Over 250 Points: Investor Sentiment Declines, Greed Index Remains In 'Fear' Zone An index measuring market sentiment based on fear and greed showed a slight increase in fear levels on Friday.
benzinga.com Nasdaq Moves Higher; US Inflation Rate Accelerates In March U.S. stocks mixed, Nasdaq up 100 points. Inflation rate surges to 3.3%. Japan's Nikkei 225 and China's Shanghai Composite close higher.
benzinga.com Trump Throws A Lifeline To Palantir, Nasdaq 100 Targets 8th Green Day: What's Moving Markets Friday? Tech stocks rise as the Nasdaq 100 targets an 8-day streak, even as inflation spikes and consumer sentiment hits a record low. Trump lifts Palantir, oil rebounds and AI chips surge on TSMC strength.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Organon, CoreWeave, WhiteFiber And Other Big Stocks Moving Higher On Friday Dow Jones fell 100 points as Sun Pharma offered 12 billion to buy Organon, Organon shares jumped 26.4%, other stocks also rose.
benzinga.com Sun Pharma Nears Final Offer For Organon In Largest Overseas Bet Sun Pharma prepares $12 billion Organon bid after due diligence, advancing financing for its biggest global acquisition push.
benzinga.com US Stocks Mixed; Dow Falls Over 100 Points US stocks mixed; Dow falls 0.29% as inflation rate surges to 3.3%. Materials up 0.8%, financials down 0.8%. Asian markets close higher.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Reported April 9: 'Sun Pharma Targets $12 Billion Acquisition of Organon' - The Economic Times https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-preps-for-12-billion-organon-bid-in-biggest-overseas-pharma-ma-by-indian-co/articleshow/130152812.cms?from=m…
- benzinga.com Organon To Present Results Of Post-Hoc Sub-Analysis Of Pooled Data From Phase 3 ADORING 1 And ADORING 2 Pivotal Trials Evaluating Efficacy And Safety Of VTAMA Cream Versus Vehicle At AAD Annual Meeting VTAMA demonstrated early and consistent response rates in disease severity and itch improvements, measured by the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) and Peak…
- benzinga.com Organon To Present Results From Sub-Analysis Of Pooled Data From Phase 3 ADORING 1 And ADORING 2 Pivotal Trials Evaluating VTAMA Cream Versus Vehicle At AAAAI Annual Meeting Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as…
benzinga.com Barclays Maintains Underweight on Organon, Raises Price Target to $8 Barclays analyst Glen Santangelo maintains Organon (NYSE:OGN) with a Underweight and raises the price target from $7.5 to $8.
benzinga.com Organon Enters Into Agreement To Exclusively License Global Rights To MIUDELLA, Sebela Pharma's Hormone-Free Copper Intrauterine Device Contraceptive MIUDELLA® is a strategic addition to Organon's portfolio, strengthening its long‑term commitment to advancing women's healthOrganon (NYSE:OGN), a global healthcare company with a mission to deliver…- benzinga.com What's Driving the Market Sentiment Around Organon & Co?
benzinga.com Organon Q4 Earnings Assessment - benzinga.com Organon Q4 Adj. EPS $0.63 Misses $0.73 Estimate, Sales $1.507B Miss $1.539B Estimate Organon (NYSE:OGN) reported quarterly earnings of $0.63 per share which missed the analyst consensus estimate of $0.73 by 14.05 percent. This is a 30 percent decrease over earnings of $0.90 per share…
benzinga.com Earnings Scheduled For February 12, 2026 
benzinga.com Earnings Preview: Organon - benzinga.com What Does the Market Think About Organon & Co?
benzinga.com Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report Sun Pharma is evaluating a potential $10 billion acquisition of Organon, a move that could become India's largest cross-border pharma deal.- benzinga.com Organon Signs Commercialization Agreement For Daiichi Sankyo's Nilemdo To Strengthen Cardiovascular Disease Portfolio In France And Nordic Countries The agreement builds on Organon's cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This…
- benzinga.com Barclays Initiates Coverage On Organon with Underweight Rating, Announces Price Target of $7.5 Barclays analyst Glen Santangelo initiates coverage on Organon (NYSE:OGN) with a Underweight rating and announces Price Target of $7.5.